Immune cell hacking is the basis of cancer treatments
Engineering strategies to overcome current roadblocks in CAR T cell therapy in mice with pancreatic cancer by making IL-2 only when encountering a cancer cell
The University of California, San Francisco led synthetic biologists who were able to reprogram CAR T Cells to make IL-2 only when they encounter a cancer cell. The team found that this IL-2 production was most efficient at fighting tumours in mice with pancreatic cancer when it was activated through a pathway that was separate from the one used to recognize the cancer cell — a detail that could help in shaping future therapies, says Andrea Schietinger, a tumour immunologist at Memorial Sloan Kettering Cancer Center in New York City.
Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat. Rev. Clin. 17, 142–137 (2020).
T cells typically patrol the body, looking for foreign proteins displayed on the surface of cells. Such cells could be infected with a virus, for example, or they could be tumour cells that are producing abnormal, cancer-associated proteins. T cells called killer T cells can destroy abnormal cells.
The Challenge of Making the Next Generation of T Cells a Living, Stable, Active Candidate Anticancer Cytokine
The approach was approved to treat certain types of leukaemias and lymphomas. But researchers have been pursuing ways to make the treatments safer and more effective, and to expand their use to other diseases.
Other synthetic circuits have been designed to allow precise regulation of CAR expression, by placing it under the control of genetic elements that activate the necessary genes in response to a drug8. Most of the complicated designs have yet to go through the safety studies required for use in people.
The ability to turn the T cells on and off could also help to reduce a phenomenon called T-cell exhaustion, in which T cells become inactive after a prolonged period of stimulation, says Evan Weber, a cancer immunologist at the Children’s Hospital of Philadelphia in Pennsylvania. Some studies have found that giving T cells a ‘rest period’ can reduce T cell exhaustion and boost their overall effectiveness against tumours3.
Even so, the challenge of making such a ‘living drug’ from a person’s cells extends beyond complicated designs. Many of the newest candidates still face safety and manufacturing problems. “There’s an explosion of very fancy things, and I think that’s great,” says immunologist Michel Sadelain at the Memorial Sloan Kettering Cancer Center in New York City. “But the complexity cannot always be brought as described into a clinical setting.”
CRISPR, T cells, and Mol. Ther. How to Engineer and Design Chimeric Antigen Receptors (Dev. 12), by Alexander Marson and Robert A. Macaulay
As yet, there are no simple solutions to any of these problems. Mackall says that they have a long way to go. “But we’re seeing promising signals now.”
CRISPR has been used to modify T cells in many other ways. Alexander Marson and his colleagues used the genome editing tool to modify the expression of thousands of genes in T cells, and then looked at the effect the changes had on the production of an immune-regulating molecule called cytokines5. In another screen using CRISPR, the team found that reducing the activity of a protein called RASA2 enhanced the ability of CAR-T cells to kill their targets6. Marson says that learning from the genes we can turn up and turn down will help them behave as they want.
Guedan, S., Calderon, H., Posey, A. D. Jr & Maus, M. V. Engineering and design of chimeric antigen receptors. It could also be calledMol. Ther. The methods are mentioned. There are 12 stories in Dev. 12.
TETonic shift in human memory T cells: Molecular heterogeneity and the fate of the H-cell/lymphoma
Pastor, W. A., Aravind, L. & Rao, A. TETonic shift: biological roles of TET proteins in DNA demethylation and transcription. Nat. Rev. The Cell Biol. 14, was published on Friday, July 13th.
Human memory T cells: generation, heterogeneity, and homeostasis. Nat. Rev. Immunol. 14, 24–35 (2014).
Watatani, Y. et al. Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. The leukemia 33 is out this year.
H. C., and Liang are authors of a book. Anaplastic large cell lymphoma has vulnerabilities in the BATF3/IL-2R-module. In the next ten years, the Nat. Commun. 12, 5577.
Nakagawa and his wife, M. et al. Targeting the HTLV-I-regulated BATF3/IRF4 transcriptional network in adult T cell leukemia/lymphoma. Cancer Cell 34, 286–297.e10 (2018).
Glucocorticoids inactivate the inflammatory response of the immune system and their relation to the T cell production in chronic Lymphocytic Leukemia
Gonzalez, M. V. Glucocorticoids antagonize AP-1 by inhibiting the activation/phosphorylation of JNK without affecting its subcellular distribution. The J. Cell Biol. 150 was published in 2000.
Patil, R. H. et al. Dexamethasone inhibits inflammatory response via down regulation of AP-1 transcription factor in human lung epithelial cells. Gene 622,– 85-94.
Man, K. et al. CD8 T cell exhaustion and limits the development of memory-like T cells are promoted by the transcription factor IRF4. The Immunity 47 is entitled 1129–1141.e5.
Logan, M. R., Jordan-Williams, K. L., Poston, S., Liao, J. & Taparowsky, E. J. Overexpression of Batf induces an apoptotic defect and an associated lymphoproliferative disorder in mice. Cell Death Dis. 3 was published in 2012
There are correlations between TET2 deficiency and hematopoietic abnormality in mice and in humans. Cancer Cell 20, 25–38 (2011).
Zhang, X. et al. DNMT3A and TET2 compete and cooperate to repress lineage-specific transcription factors in hematopoietic stem cells. Nat. Genet. This is 48, 1014–1023.
Kong, W. T cells that are exhausted in chronic Lymphocytic leukemia are rejuvenated by reverting to the chimeric antigen Receptor. J. Clin. Invest. 131, e145459 (2021).
The effect of genetically-designed retroviral vectors on human deaminase in murine bone marrow transplant recipients
The effects of retroviral vectors design on human deaminase in murine bone marrow transplant recipients. Proc. The Natl Acad. is a state of the art science. The USA 92, 6733–6737 was published by the Sociology of USA.
Gallardo, H. F., Tan, C., Ory, D. & Sadelain, M. Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes. Blood 90, 952–957 (1997).
Stephan, M. T., and others. The CD80 and 4-1BBL induce auto- and transcostimulation, leading to a potent rejection tumor. The Nat. Med. was published in February of 2007.
M. C. and Gong were involved in a project. Cancer patient T cells genetically targeted to a specific area of the body allow them to release cytokines and lyse cancer cells. Neoplasia 1, 123–128, was published in 1999.
R.J., D.L., and G.P. were identified. There are rapid T cells that rapidly induce a cure in adults with Acute lymphatic Leukemia. Sci. Transl Med. 5, 177ra138 (2013).
The combination of IL 15/IL-15R immunotherapy maximizes activity in the body. J. Immunol. 177, 6072–6080 (2006).
Direct genotyping of multiple unknown flanking DNA in highly complex chromatin samples. The case of a single viral infection identified by a gene transfer method
A method of transposition of native chromatin for fast and sensitive profiling of open chromatin. Nat. Methods 10 was published in 2013).
M. et al. Direct genotyping of multiple rare unknown flanking DNA in highly complex samples. Hum. Gene Ther is a man. The year 2001 saw the number of 12, 743–749.
There are time- efficient and accurate analysis of viral integration events in large-scale gene therapy data. Mol. Ther. The Acids of Nucleic Acids 6, 133–131 were published in the year.